SCHEMBL1758405

SCHEMBL1758405

Cc1ccc(F)cc1NC=O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MAPT P10636 4/20 0.42
HTT P42858 1/20 0.42
ALDH1A1 P00352 4/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 2/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
ESR1 P03372 1/20 0.38
CLCN2 P51788 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1759061 0.79 MAPT (0.39) PKMMAPTHTTALDH1A1MEN1
SCHEMBL1758619 0.79 MEN1 (0.50) HTTALDH1A1HPGDMEN1KMT2A
SCHEMBL9597648 0.78 ALDH1A1 (0.41) RXFP1MAPTHTTALDH1A1MEN1
SCHEMBL9138744 0.76 ALDH1A1 (0.46) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL1758540 0.76 RAPGEF4 (0.50) MAPTHTTALDH1A1KMT2AKDM4E
SCHEMBL18228323 0.76 MEN1 (0.37) PKMMAPTALDH1A1MEN1KMT2A
SCHEMBL5464068 0.76 CYP3A4 (0.53) PKMMAPTHTTALDH1A1HPGD
SCHEMBL24575887 0.76 ADRA2A (0.43) MAPTHTTALDH1A1MEN1KMT2A
SCHEMBL19677081 0.76 HTT (0.48) PKMMAPTHTTALDH1A1HPGD
SCHEMBL988638 0.75 ALDH1A1 (0.47) PKMMAPTHTTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP claimed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US claimed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO claimed
CN-108314648-A The synthetic method of the bromo- 7- fluorine isoquinolin of 4- 苏州康润医药有限公司 2018-07-24 CN disclosed
CN-105121430-B Conditioning agent for treating the LADA orphan receptor γ related to the biostearin of inflammatory disease (ROR γ) 葛兰素集团有限公司 2017-06-16 CN disclosed
EP-2493886-B1 HETEROARYL PIPERIDINE AND PIPERAZINE DERIVATES BAYER CROPSCIENCE AG (DE) 2014-11-26 EP disclosed
US-8501781-B2 Heteroarylpiperidine and -piperazine derivatives BAYER CROPSCIENCE AG (DE) 2013-08-06 US disclosed
EP-2493886-A1 HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES Bayer CropScience AG (DE) 2012-09-05 EP disclosed
US-20110306620-A1 Heteroarylpiperidine And-Piperazine Derivatives BAYER CROPSCIENCE AG (DE) 2011-12-15 US disclosed
WO-2011051244-A1 HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2011-05-05 WO disclosed
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP disclosed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US disclosed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306620-A1 Heteroarylpiperidine And-Piperazine Derivatives CAT, DPM1, ERG28 PKM 1007/4885RXFP1 4657/4885MAPT 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.